Two Draft Guidances Set Up FDA’s Plans To Gather Postmarket Data
Executive Summary
The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.